Notice2024-23698
Foreign-Trade Zone (FTZ) 235, Notification of Proposed Production Activity; Renaissance Lakewood, LLC; (Prescription Nasal Spray Products); Lakewood, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 15, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 199 (Tuesday, October 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 199 (Tuesday, October 15, 2024)]
[Notices]
[Pages 82971-82972]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-23698]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-52-2024]
Foreign-Trade Zone (FTZ) 235, Notification of Proposed Production
Activity; Renaissance Lakewood, LLC; (Prescription Nasal Spray
Products); Lakewood, New Jersey
The Township of Lakewood, grantee of FTZ 235, submitted a
notification of proposed production activity to the FTZ Board (the
Board) on behalf of Renaissance Lakewood, LLC (Renaissance) for
Renaissance's facilities in Lakewood, New Jersey within FTZ 235. The
notification conforming to the requirements of the Board's regulations
(15 CFR 400.22) was received on September 30, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material/component and specific
finished product(s) described in the submitted notification (summarized
below) and subsequently authorized by the Board. The benefits that may
stem from conducting production activity under FTZ procedures are
explained in the background section of the Board's website--accessible
via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products include calcitonin gene-related
peptide receptor antagonist (prescription nasal spray-packaged) and
calcitonin gene-related peptide receptor antagonist (prescription nasal
spray-unpackaged) (duty-free).
The proposed foreign-status material/component includes zavegepant
hydrochloride (active pharmaceutical ingredient) (duty rate of 6.5%).
The request indicates that certain materials/components are subject to
duties under section 301 of the Trade Act of 1974 (section 301),
depending on the country of origin. The applicable section 301
decisions require subject merchandise to be admitted to FTZs in
privileged foreign status (19 CFR 146.41).
[[Page 82972]]
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#3c5a48467c484e5d5859125b534a"><span class="__cf_email__" data-cfemail="a3c5d7d9e3d7d1c2c7c68dc4ccd5">[email protected]</span></a>. The closing period for their receipt is November 25,
2024.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Kolade Osho at
<a href="/cdn-cgi/l/email-protection#91dafefdf0f5f4bfdee2f9fed1e5e3f0f5f4bff6fee7"><span class="__cf_email__" data-cfemail="b0fbdfdcd1d4d59effc3d8dff0c4c2d1d4d59ed7dfc6">[email protected]</span></a>.
Dated: October 8, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-23698 Filed 10-11-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.